Positive efficacy and safety data were observed at 3 months after a single injection of K8 in this study conducted at the University of Kentucky.

PulseSight Therapeutics SAS, an ophthalmology biotech company developing disruptive non-viral vectorized therapies with minimally-invasive delivery technology, today announces the first close of its ...

Apellis Pharma has become the first company to claim FDA approval for a drug to treat geographic atrophy ... the loss of photoreceptors and retinal pigment epithelial (RPE) cells, the central ...

"We are pleased with the FDA's decision to extend the use of IZERVAY for longer-term administration—further solidifying IZERVAY's status as a trusted choice for thousands of GA patients since ...

for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). As a result, IZERVAY is now approved without a limitation on duration of dosing—providing ...

Astellas confirmed today that it will withdraw its EMA filing for avacincaptad pegol as a treatment for eye disorder geographic atrophy (GA), based on feedback from the EU regulator. It is a major ...

(TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced the U.S. Food and Drug Administration (FDA) approved expanded U.S. Prescribing information for IZERVAY™ (avacincaptad pegol ...

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic ...

EYLEA’s unique MoA: What is the rationale for the higher molar dose?

EYLEA’s unique MoA: What is the rationale for the higher molar dose?

Heterogeneous Turkey shows influences from the Middle East, Mediterranean, the Balkan peninsula, and Central Asia, but it’s much more than its clichéd image of where East meets West. Stylish ...